Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TraMag (TM) is an oral small molecule combination therapy developed by Orphinic Scientific, consisting of the opioid analgesic tramadol and magnesium. It is primarily indicated for the treatment of pain, specifically in the context of osteoarthritis. Tramadol acts as a mu-opioid receptor agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI), while the addition of magnesium is intended to potentially enhance analgesic efficacy or mitigate side effects, possibly through NMDA receptor modulation. The product is currently in the certification and market authorization phase, following clinical development for pain management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TraMag.